open access

Vol 73, No 3 (2022)
Guidelines / Expert consensus
Submitted: 2022-05-03
Accepted: 2022-05-04
Published online: 2022-06-30
Get Citation

Gastroduodenal neuroendocrine neoplasms including gastrinoma — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]

Grażyna Rydzewska1, Janusz Strzelczyk2, Tomasz Bednarczuk3, Marek Bolanowski4, Małgorzata Borowska5, Ewa Chmielik6, Jarosław B. Ćwikła7, Wanda Foltyn2, Iwona Gisterek8, Daria Handkiewicz-Junak9, Alicja Hubalewska-Dydejczyk10, Ksenia Janas2, Michał Jarząb11, Roman Junik12, Dariusz Kajdaniuk13, Grzegorz Kamiński14, Agnieszka Kolasińska-Ćwikła15, Magorzata Kołos, Aldona Kowalska16, Leszek Królicki17, Jolanta Kunikowska17, Katarzyna Kuśnierz18, Andrzej Lewiński19, Łukasz Liszka20, Magdalena Londzin-Olesik2, Bogdan Marek13, Anna Malczewska2, Anna Nasierowska-Guttmejer21, Ewa Nowakowska-Duława22, Marianne E. Pavel23, Joanna Pilch-Kowalczyk24, Jarosław Reguła25, Violetta Rosiek2, Marek Ruchała26, Lucyna Siemińska13, Anna Sowa-Staszczak10, Teresa Starzyńska27, Zoran Stojčev28, Michał Studniarek29, Anhelli Syrenicz30, Marek Szczepkowski31, Ewa Wachuła32, Wojciech Zajęcki5, Anna Zemczak2, Wojciech Zgliczyński33, Krzysztof Zieniewicz34, Beata Kos-Kudła2
·
Pubmed: 36059172
·
Endokrynol Pol 2022;73(3):455-490.
Affiliations
  1. Department of Internal Medicine and Gastroenterology, Central Clinical Hospital of the Ministry of Interior and Administration, Warsaw, Poland
  2. Department of Endocrinology and Neuroendocrine Tumours, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
  3. Department of Internal Medicine and Endocrinology, Medical University of Warsaw, Warsaw, Poland
  4. Chair and Department of Endocrinology, Diabetes, and Isotope Therapy, Medical University of Wroclaw, Wroclaw, Poland
  5. Department of Endocrinology and Neuroendocrine Tumours, Medical University of Silesia, Katowice, Poland
  6. Tumor Pathology Department, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  7. Department of Cardiology and Internal Medicine, Collegium Medicum, University of Warmia and Mazury, Olsztyn, Poland
  8. Chair of Oncology and Radiotherapy, Medical University of Silesia, Katowice, Poland
  9. Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Brench, Gliwice, Poland
  10. Chair and Department of Endocrinology, Jagiellonian University Medical College, Cracow, Poland
  11. Breast Unit, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland
  12. Department of Endocrinology and Diabetology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Bydgoszcz, Poland
  13. Division of Pathophysiology, Department of Pathophysiology and Endocrinology, Medical University of Silesia, Katowice, Poland
  14. Department of Endocrinology and Radioisotope Therapy, Military Institute of Medicine, Warsaw, Poland
  15. Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland
  16. Department of Endocrinology, Holycross Cancer Centre, Collegium Medicum, Jan Kochanowski University, Kielce, Poland
  17. Nuclear Medicine Department, Medical University of Warsaw, Warsaw, Poland
  18. Department of Gastrointestinal Surgery, Medical University of Silesia, Katowice, Poland
  19. Department of Endocrinology and Metabolic Diseases, Medical University of Lodz, Lodz, Poland
  20. Department of Pathomorphology and Molecular Diagnostics, Medical University of Silesia, Katowice, Poland
  21. Faculty of Medicine, Lazarski University in Warsaw, Warsaw, Poland
  22. Department of Gastroenterology and Hepatology, Medical University of Silesia, Katowice, Poland
  23. Department of Medicine 1, Endocrinology and Diabetology, Friedrich Alexander University of Erlangen-Nürnberg, Erlangen, Germany
  24. Department of Radiology and Nuclear Medicine, Medical University of Silesia, Katowice, Poland;
  25. Department of Oncological Gastroenterology, Maria Sklodowska-Curie Memorial National Research Institute of Oncology, Warsaw, Poland
  26. Department of Endocrinology, Metabolism and Internal Diseases, Medical University in Poznan, Poznan, Poland
  27. Department of Gastroenterology, Medical Pomeranian University in Szczecin, Szczecin, Poland
  28. Department of Oncology and Breast Diseases, Centre of Postgraduate Medical Education, Warsaw, Poland
  29. Department of Radiology, Medical University of Gdansk, Gdansk, Poland
  30. Department of Endocrinology, Metabolic and Internal Diseases, Pomeranian Medical University, Szczecin, Poland
  31. Clinical Department of Colorectal, General and Oncological Surgery, Centre of Postgraduate Medical Education, Warsaw, Poland
  32. Department of Clinical Oncology, Gdynia Oncology Centre of the Polish Red Cross Maritime Hospital, Gdynia, Poland
  33. Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland
  34. Chair and Department of General, Transplant, and Liver Surgery, Medical University of Warsaw, Warsaw, Poland

open access

Vol 73, No 3 (2022)
Guidelines
Submitted: 2022-05-03
Accepted: 2022-05-04
Published online: 2022-06-30

Abstract

After another meeting of experts of the Polish Network of Neuroendocrine Tumours, updated recommendations for the management of patients with gastric and duodenal neuroendocrine neoplasms, including gastrinoma, have been issued. As before, the epidemiology, pathogenesis and clinical symptoms of these neoplasms have been discussed, as well as the principles of diagnostic procedures, including biochemical and histopathological diagnostics and tumour localisation, highlighting the changes introduced in the recommendations. Updated principles of therapeutic management have also been presented, including endoscopic and surgical treatment, and the options of pharmacological and radioisotope treatment. The importance of monitoring patients with gastric and duodenal NENs, including gastrinoma, has also been emphasised.

Abstract

After another meeting of experts of the Polish Network of Neuroendocrine Tumours, updated recommendations for the management of patients with gastric and duodenal neuroendocrine neoplasms, including gastrinoma, have been issued. As before, the epidemiology, pathogenesis and clinical symptoms of these neoplasms have been discussed, as well as the principles of diagnostic procedures, including biochemical and histopathological diagnostics and tumour localisation, highlighting the changes introduced in the recommendations. Updated principles of therapeutic management have also been presented, including endoscopic and surgical treatment, and the options of pharmacological and radioisotope treatment. The importance of monitoring patients with gastric and duodenal NENs, including gastrinoma, has also been emphasised.

Get Citation

Keywords

neuroendocrine neoplasms; stomach; duodenum; gastrinoma; diagnostics; therapy; recommendations

Supp./Additional Files (2)
Supplementary File [Materiały dodatkowe] — Tab. S1, S2
Download
81KB
Conflict of interests [Konflikt interesów]
Download
429KB
About this article
Title

Gastroduodenal neuroendocrine neoplasms including gastrinoma — update of the diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours) [Nowotwory neuroendokrynne żołądka i dwunastnicy z uwzględnieniem gastrinoma — uaktualnione zasady postępowania (rekomendowane przez Polską Sieć Guzów Neuroendokrynnych)]

Journal

Endokrynologia Polska

Issue

Vol 73, No 3 (2022)

Article type

Guidelines / Expert consensus

Pages

455-490

Published online

2022-06-30

Page views

5825

Article views/downloads

1856

DOI

10.5603/EP.a2022.0051

Pubmed

36059172

Bibliographic record

Endokrynol Pol 2022;73(3):455-490.

Keywords

neuroendocrine neoplasms
stomach
duodenum
gastrinoma
diagnostics
therapy
recommendations

Authors

Grażyna Rydzewska
Janusz Strzelczyk
Tomasz Bednarczuk
Marek Bolanowski
Małgorzata Borowska
Ewa Chmielik
Jarosław B. Ćwikła
Wanda Foltyn
Iwona Gisterek
Daria Handkiewicz-Junak
Alicja Hubalewska-Dydejczyk
Ksenia Janas
Michał Jarząb
Roman Junik
Dariusz Kajdaniuk
Grzegorz Kamiński
Agnieszka Kolasińska-Ćwikła
Magorzata Kołos
Aldona Kowalska
Leszek Królicki
Jolanta Kunikowska
Katarzyna Kuśnierz
Andrzej Lewiński
Łukasz Liszka
Magdalena Londzin-Olesik
Bogdan Marek
Anna Malczewska
Anna Nasierowska-Guttmejer
Ewa Nowakowska-Duława
Marianne E. Pavel
Joanna Pilch-Kowalczyk
Jarosław Reguła
Violetta Rosiek
Marek Ruchała
Lucyna Siemińska
Anna Sowa-Staszczak
Teresa Starzyńska
Zoran Stojčev
Michał Studniarek
Anhelli Syrenicz
Marek Szczepkowski
Ewa Wachuła
Wojciech Zajęcki
Anna Zemczak
Wojciech Zgliczyński
Krzysztof Zieniewicz
Beata Kos-Kudła

References (96)
  1. Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010; 17(4): 909–918.
  2. Roberto GA, Rodrigues CM, Peixoto RD, et al. Gastric neuroendocrine tumor: A practical literature review. World J Gastrointest Oncol. 2020; 12(8): 850–856.
  3. Gluckman CR, Metz DC. Gastric Neuroendocrine Tumors (Carcinoids). Curr Gastroenterol Rep. 2019; 21(4): 13.
  4. O'Toole D, Delle Fave G, Jensen RT. Gastric and duodenal neuroendocrine tumours. Best Pract Res Clin Gastroenterol. 2012; 26(6): 719–735.
  5. Delle Fave G, O'Toole D, Sundin A, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology. 2016; 103(2): 119–124.
  6. O'Connor JM, Marmissolle F, Bestani C, et al. Observational study of patients with gastroenteropancreatic and bronchial neuroendocrine tumors in Argentina: Results from the large database of a multidisciplinary group clinical multicenter study. Mol Clin Oncol. 2014; 2(5): 673–684.
  7. Wang R, Zheng-Pywell R, Chen HA, et al. Management of Gastrointestinal Neuroendocrine Tumors. Clin Med Insights Endocrinol Diabetes. 2019; 12: 1179551419884058.
  8. Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015; 121(4): 589–597.
  9. Yao JC, Hassan M, Phan A, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008; 26(18): 3063–3072.
  10. Dias AR, Azevedo BC, Alban LB, et al. GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE. Arq Bras Cir Dig. 2017; 30(2): 150–154.
  11. Mastracci L, Rindi G, Grillo F, et al. Neuroendocrine neoplasms of the esophagus and stomach. Pathologica. 2021; 113(1): 5–11.
  12. WHO Classification of Tumours Editorial Board 2019. WHO Classification of Tumours. 5th Edition. Digestive System Tumours. IARC Press, Lyon 2019.
  13. Kunz P, Reidy-Lagunes D, Anthony L, et al. Consensus Guidelines for the Management and Treatment of Neuroendocrine Tumors. Pancreas. 2013; 42(4): 557–577.
  14. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007; 21(1): 15–31.
  15. Merola E, Sbrozzi-Vanni A, Panzuto F, et al. Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology. 2012; 95(3): 207–213.
  16. Kos-Kudła B, Blicharz-Dorniak J, Strzelczyk J, et al. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2017; 68(2): 79–110.
  17. Borch K, Ahrén Bo, Ahlman H, et al. Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg. 2005; 242(1): 64–73.
  18. Plöckinger U. Diagnosis and Treatment of Gastrinomas in Multiple Endocrine Neoplasia Type 1 (MEN-1). Cancers (Basel). 2012; 4(1): 39–54.
  19. WHO Classification of Tumours of the Digestive System. IARC, Lyon 2017.
  20. Delle Fave G, Kwekkeboom DJ, Van Cutsem E, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms. Neuroendocrinology. 2012; 95(2): 74–87.
  21. Jensen RT, Rindi G, Arnold R, et al. Frascati Consensus Conference, European Neuroendocrine Tumor Society. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006; 84(3): 165–172.
  22. Lee KJ, Cho JH, Lee SH, et al. Clinicopathological characteristics of biliary neuroendocrine neoplasms: a multicenter study. Scand J Gastroenterol. 2017; 52(4): 437–441.
  23. Dumitrascu T, Dima S, Herlea V, et al. Neuroendocrine tumours of the ampulla of Vater: clinico-pathological features, surgical approach and assessment of prognosis. Langenbecks Arch Surg. 2012; 397(6): 933–943.
  24. Garbrecht N, Anlauf M, Schmitt A, et al. Somatostatin-producing neuroendocrine tumors of the duodenum and pancreas: incidence, types, biological behavior, association with inherited syndromes, and functional activity. Endocr Relat Cancer. 2008; 15(1): 229–241.
  25. Kos-Kudła B, Foltyn W, Malczewska A, et al. Update of the diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022; 73(3): 387–423.
  26. Ruszniewski P, Delle Fave G, Cadiot G, et al. Frascati Consensus Conference, European neuroendocrine Tumor Society. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology. 2006; 84(3): 158–164.
  27. Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg. 2009; 46(1): 13–106.
  28. Jensen RT, Niederle B, Mitry E, et al. Frascati Consensus Conference, European Neuroendocrine Tumor Society. Gastrinoma (duodenal and pancreatic). Neuroendocrinology. 2006; 84(3): 173–182.
  29. Wilson SD, Doffek KM, Krzywda EA, et al. Zollinger-Ellison syndrome associated with a history of alcohol abuse: coincidence or consequence? Surgery. 2011; 150(6): 1129–1135.
  30. Anlauf M, Garbrecht N, Henopp T, et al. Sporadic versus hereditary gastrinomas of the duodenum and pancreas: distinct clinico-pathological and epidemiological features. World J Gastroenterol. 2006; 12(34): 5440–5446.
  31. Thakker RV, Newey PJ, Walls GV, et al. Endocrine Society. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012; 97(9): 2990–3011.
  32. Harper S, Carroll RW, Frilling A, et al. Primary lymph node gastrinoma: 2 cases and a review of the literature. J Gastrointest Surg. 2015; 19(4): 651–655.
  33. Lu X, Aoun E, Morrissey S. Primary hepatic gastrinoma presenting as vague gastrointestinal symptoms. BMJ Case Rep. 2012; 2012.
  34. Naoe H, Iwasaki H, Kawasaki T, et al. Primary hepatic gastrinoma as an unusual manifestation of zollinger-ellison syndrome. Case Rep Gastroenterol. 2012; 6(3): 590–595.
  35. Ogawa S, Wada M, Fukushima M, et al. Case of primary hepatic gastrinoma: Diagnostic usefulness of the selective arterial calcium injection test. Hepatol Res. 2015; 45(7): 823–826.
  36. Tonelli F, Giudici F, Nesi G, et al. Biliary tree gastrinomas in multiple endocrine neoplasia type 1 syndrome. World J Gastroenterol. 2013; 19(45): 8312–8320.
  37. Ramage JK, Ahmed A, Ardill J, et al. UK and Ireland Neuroendocrine Tumour Society. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut. 2012; 61(1): 6–32.
  38. Jensen RT, Cadiot G, Brandi ML, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012; 95(2): 98–119.
  39. Hoffmann KM, Furukawa M, Jensen RT. Duodenal neuroendocrine tumors: Classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol. 2005; 19(5): 675–697.
  40. Kos-Kudła B, Blicharz-Dorniak J, Handkiewicz-Junak D, et al. Consensus Conference, Polish Network of Neuroendocrine Tumours. Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 418–443.
  41. de Herder WW. Biochemistry of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007; 21(1): 33–41.
  42. Grozinsky-Glasberg S, Kaltsas G, Gur C, et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol. 2008; 159(4): 475–482.
  43. Vannella L, Sbrozzi-Vanni A, Lahner E, et al. Development of type I gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011; 33(12): 1361–1369.
  44. Rehfeld JF, Federspiel B, Bardram L. A neuroendocrine tumor syndrome from cholecystokinin secretion. N Engl J Med. 2013; 368(12): 1165–1166.
  45. Gonzalez RS. Diagnosis and Management of Gastrointestinal Neuroendocrine Neoplasms. Surg Pathol Clin. 2020; 13(3): 377–397.
  46. Asa SL, La Rosa S, Mete O. (eds). The spectrum of neuroendocrine neoplasia. A Practical Approach to Diagnosis, Classification and Therapy. Springer 2021.
  47. La Rosa S, Vanoli A. Gastric neuroendocrine neoplasms and related precursor lesions. J Clin Pathol. 2014; 67(11): 938–948.
  48. Abraham SC, Carney JA, Ooi A, et al. Achlorhydria, parietal cell hyperplasia, and multiple gastric carcinoids: a new disorder. Am J Surg Pathol. 2005; 29(7): 969–975.
  49. AJCC Cancer Staging Manual. 8 th ed. Springer 2017.
  50. Milione M, Parente P, Grillo F, et al. Neuroendocrine neoplasms of the duodenum, ampullary region, jejunum and ileum. Pathologica. 2021; 113(1): 12–18.
  51. Makhlouf H, Burke A, Sobin L. Carcinoid tumors of the ampulla of Vater. Cancer. 1999; 85(6): 1241–1249, doi: 10.1002/(sici)1097-0142(19990315)85:6<1241::aid-cncr5>3.0.co;2-4.
  52. Hwang S, Lee SG, Lee YJ, et al. Radical surgical resection for carcinoid tumors of the ampulla. J Gastrointest Surg. 2008; 12(4): 713–717.
  53. Inai K, Kobuke T, Yonehara S, et al. Duodenal gangliocytic paraganglioma with lymph node metastasis in a 17-year-old boy. Cancer. 1989; 63(12): 2540–2545, doi: 10.1002/1097-0142(19890615)63:12<2540::aid-cncr2820631231>3.0.co;2-h.
  54. Ming SC, Goldman H. Pathology of gastrointestinal tract. 2nd ed. Williams & Wilkins 1998.
  55. Zimmer T, Ziegler K, Liehr RM, et al. Endosonography of neuroendocrine tumors of the stomach, duodenum, and pancreas. Ann N Y Acad Sci. 1994; 733: 425–436.
  56. Pilch-Kowalczyk J, Leszczyński S. Układ trawienny. In: Leszczyński S, Pilch-Kowalczyk J. ed. Diagnostyka obrazowa. Układ trawienny. PZWL, Warszawa 2012: Warszawa.
  57. Ricke J, Klose KJ. Imaging procedures in neuroendocrine tumours. Digestion. 2000; 62 Suppl 1: 39–44.
  58. Flechsig P, Zechmann CM, Schreiweis J, et al. Qualitative and quantitative image analysis of CT and MR imaging in patients with neuroendocrine liver metastases in comparison to (68)Ga-DOTATOC PET. Eur J Radiol. 2015; 84(8): 1593–1600.
  59. Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013; 40(5): 800–816.
  60. Kwon D, Nakakura E, Bergsland E, et al. Gastric neuroendocrine tumors: management and challenges. Gastrointestinal Cancer: Targets and Therapy. 2017; 7: 31–37.
  61. Eto K, Yoshida N, Iwagami S, et al. Surgical treatment for gastrointestinal neuroendocrine tumors. Ann Gastroenterol Surg. 2020; 4(6): 652–659.
  62. Tsoli M, Chatzellis E, Koumarianou A, et al. Current best practice in the management of neuroendocrine tumors. Ther Adv Endocrinol Metab. 2019; 10: 2042018818804698.
  63. Kwon YH, Jeon SW, Kim GHa, et al. Long-term follow up of endoscopic resection for type 3 gastric NET. World J Gastroenterol. 2013; 19(46): 8703–8708.
  64. Lipiński M, Rydzewska G, Foltyn W, et al. Gastroduodenal neuroendocrine neoplasms, including gastrinoma - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2017; 68(2): 138–153.
  65. Kos-Kudła B, Rosiek V, Borowska M, et al. Pancreatic neuroendocrine neoplasms — update ofthe diagnostic and therapeutic guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2022; 73(3): 491–521.
  66. Pavel M, Öberg K, Falconi M, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020; 31(7): 844–860.
  67. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020; 49(1): 1–33.
  68. Norton JA, Foster DS, Ito T, et al. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018; 47(3): 577–601.
  69. Jianu CS, Fossmark R, Syversen U, et al. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol. 2011; 46(4): 456–463.
  70. Fossmark R, Sørdal Ø, Jianu CS, et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther. 2012; 36(11-12): 1067–1075.
  71. Moore AR, Boyce M, Steele IA, et al. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One. 2013; 8(10): e76462.
  72. Lew E, Pisegna J, Starr J, et al. Intravenous pantoprazole rapidly controls gastric acid hypersecretion in patients with Zollinger–Ellison syndrome. Gastroenterology. 2000; 118(4): 696–704.
  73. Wilcox CM, Hirschowitz BI. Treatment strategies for Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2009; 10(7): 1145–1157.
  74. Ojeaburu JV, Ito T, Crafa P, et al. Mechanism of acid hypersecretion post curative gastrinoma resection. Dig Dis Sci. 2011; 56(1): 139–154.
  75. Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol. 2012; 10(2): 199–202.
  76. Nieto JM, Pisegna JR. The role of proton pump inhibitors in the treatment of Zollinger-Ellison syndrome. Expert Opin Pharmacother. 2006; 7(2): 169–175.
  77. Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther. 2015; 41(11): 1162–1174.
  78. Yadlapati R, Kahrilas PJ, Aronson JK, et al. SIF-AIGO-FIMMG Group, Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1): 179.
  79. Schnoll-Sussman F, Katz PO. Clinical Implications of Emerging Data on the Safety of Proton Pump Inhibitors. Curr Treat Options Gastroenterol. 2017; 15(1): 1–9.
  80. Yao J, Fazio N, Singh S, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016; 387(10022): 968–977.
  81. Ma F, Wang B, Xue L, et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020; 146(8): 2135–2142.
  82. Lin JP, Zhao YJ, He QL, et al. Adjuvant chemotherapy for patients with gastric neuroendocrine carcinomas or mixed adenoneuroendocrine carcinomas. Br J Surg. 2020; 107(9): 1163–1170.
  83. Liu DJ, Fu XL, Liu W, et al. Clinicopathological, treatment, and prognosis study of 43 gastric neuroendocrine carcinomas. World J Gastroenterol. 2017; 23(3): 516–524.
  84. Ma F, Wang B, Xue L, et al. Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. J Cancer Res Clin Oncol. 2020; 146(8): 2135–2142.
  85. Jiao X, Wang Z, Peng X, et al. Effects of tumor types on treatment strategy formulation and prognostic evaluation of gastric neuroendocrine tumors. Future Oncol. 2020; 16(28): 2197–2207.
  86. Baum RP, Kulkarni HR, Singh A, et al. Results and adverse events of personalized peptide receptor radionuclide therapy with Yttrium and Lutetium in 1048 patients with neuroendocrine neoplasms. Oncotarget. 2018; 9(24): 16932–16950.
  87. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-Term Efficacy, Survival, and Safety of [Lu-DOTA,Tyr]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017; 23(16): 4617–4624.
  88. Liu Q, Zang J, Sui H, et al. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of Lu-DOTA-EB-TATE. J Nucl Med. 2021; 62(3): 386–392.
  89. Sitani K, Parghane RV, Talole S, et al. Long-term outcome of indigenous Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a large tertiary care setting. Br J Radiol. 2021; 94(1117): 20201041.
  90. Kipnis ST, Hung M, Kumar S, et al. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. JAMA Netw Open. 2021; 4(3): e212274.
  91. Ambrosini V, Kunikowska J, Baudin E, et al. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021; 146: 56–73.
  92. Sygula A, Handkiewicz-Junak D, Kotecka-Blicharz A, et al. Consolidation treatment with somatoatatin analogues after radiopeptide therapy. Endocrine Abstracts. 2014.
  93. Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Y/Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: a 10-year study. Ann Nucl Med. 2017; 31(5): 347–356.
  94. Kunikowska J, Zemczak A, Kołodziej M, et al. Tandem peptide receptor radionuclide therapy using Y/Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging. 2020; 47(4): 922–933.
  95. European Society for Medical Oncology. Standard Operating Procedures (SOPs) for Authors and templates for ESMO Clinical Practice Guidelines (CPGs) and ESMO-MCBS Scores 2021. https://www.esmo.org/content/download/77789/1426712/file/ESMO-Clinical-Practice-Guidelines-Standard-Operating-Procedures.pdf.
  96. The National Comprehensive Cancer Network. About the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2020. https://www.nccn.org/professionals/default.aspx.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl